{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:16:30Z","timestamp":1787166990025,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bioorg.2024.107295","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T12:06:36Z","timestamp":1710590796000},"page":"107295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Multivalent pyrrolidines acting as pharmacological chaperones against Gaucher disease"],"prefix":"10.1016","volume":"146","author":[{"given":"Marc","family":"Borie-Guichot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My","family":"Lan Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelouahd","family":"Oukhrib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric-Olivier","family":"Turrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Levade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"G\u00e9nisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Ballereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Dehoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107295_b0005","first-page":"274","article-title":"Pharmacotherapy of gaucher disease: current and future options","volume":"43","author":"Bennett","year":"2018","journal-title":"P t."},{"key":"10.1016\/j.bioorg.2024.107295_b0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107295_b0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bioorg.2024.107295_b0020","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10571-015-0176-8","article-title":"Gaucher-associated Parkinsonism","volume":"35","author":"Li","year":"2015","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2024.107295_b0025","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-020-00746-0","article-title":"Enhancing the activity of glucocerebrosidase as a treatment for Parkinson disease","volume":"34","author":"Menozzi","year":"2020","journal-title":"CNS Drugs."},{"key":"10.1016\/j.bioorg.2024.107295_b0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.biochi.2015.11.009","article-title":"Glucosylceramidases and malignancies in mammals","volume":"125","author":"Astudillo","year":"2016","journal-title":"Biochimie."},{"key":"10.1016\/j.bioorg.2024.107295_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom11121775","article-title":"Therapeutic approaches in lysosomal storage diseases","volume":"11","author":"Fern\u00e1ndez-Pereira","year":"2021","journal-title":"Biomolecules."},{"key":"10.1016\/j.bioorg.2024.107295_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175023","article-title":"Update of treatment for gaucher disease","volume":"926","author":"Kong","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107295_b0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/ijms21020489","article-title":"Pharmacological chaperones: a therapeutic approach for diseases caused by destabilizing missense mutations","volume":"21","author":"Liguori","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107295_b0050","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.52586\/5056","article-title":"Role of misfolding in rare enzymatic deficits and use of pharmacological chaperones as therapeutic approach","volume":"26","author":"Pampalone","year":"2021","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bioorg.2024.107295_b0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase a in fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2024.107295_b0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/physrev.00029.2016","article-title":"Pharmacoperones as novel therapeutics for diverse protein conformational diseases","volume":"98","author":"Tao","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bioorg.2024.107295_b0065","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1039\/C7SC04712F","article-title":"Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones","volume":"9","author":"Pereira","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2024.107295_b0070","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.3390\/molecules26237223","article-title":"Pharmacological chaperone therapy for pompe disease","volume":"26","author":"Borie-Guichot","year":"2021","journal-title":"Molecules."},{"key":"10.1016\/j.bioorg.2024.107295_b0075","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/jnr.23755","article-title":"Chaperones as potential therapeutics for krabbe disease","volume":"94","author":"Graziano","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bioorg.2024.107295_b0080","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1021\/acs.jmedchem.9b00153","article-title":"Ortiz mellet, Pharmacological chaperones for the treatment of \u03b1-Mannosidosis","volume":"62","author":"R\u00edsquez-Cuadro","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0085","first-page":"1","article-title":"Advances in the development of pharmacological chaperones for the mucopolysaccharidoses","volume":"21","author":"D\u00edaz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107295_b0090","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/ph15070823","article-title":"GCase enhancers: a potential therapeutic option for gaucher disease and other neurological Disorders","volume":"15","author":"Mart\u00ednez-Bail\u00e9n","year":"2022","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.bioorg.2024.107295_b0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bioorg.2024.107295_b0100","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid \u03b2-glucosidase in gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2024.107295_b0105","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/cbic.200800249","article-title":"Isofagomine induced stabilization of glucocerebrosidase","volume":"9","author":"Kornhaber","year":"2008","journal-title":"ChemBioChem."},{"key":"10.1016\/j.bioorg.2024.107295_b0110","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbrc.2008.02.125","article-title":"Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase","volume":"369","author":"Shen","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2024.107295_b0115","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the gaucher disease L444P mutant form of \u03b2-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2024.107295_b0120","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cbic.201100332","article-title":"Synthesis, kinetic evaluation and cell-based analysis of C-alkylated isofagomines as chaperones of \u03b2-glucocerebrosidase","volume":"12","author":"Hill","year":"2011","journal-title":"ChemBioChem."},{"key":"10.1016\/j.bioorg.2024.107295_b0125","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Nonlinear partial differential equations and applications: chemical chaperones increase the cellular activity of N370S -glucosidase: a therapeutic strategy for gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2024.107295_b0130","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1021\/jm300342q","article-title":"Potent aminocyclitol glucocerebrosidase inhibitors are Subnanomolar Pharmacological chaperones for treating gaucher disease","volume":"55","author":"Trapero","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0135","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1016\/j.bmc.2006.08.003","article-title":"\u03b1-1-C-Octyl-1-deoxynojirimycin as a pharmacological chaperone for gaucher disease","volume":"14","author":"Yu","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0140","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1039\/C5OB02223A","article-title":"Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for gaucher disease","volume":"14","author":"Kato","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0145","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bioorg.2019.02.025","article-title":"Exploring substituent diversity on pyrrolidine-aryltriazole iminosugars: structural basis of \u03b2-glucocerebrosidase inhibition","volume":"86","author":"Mart\u00ednez-Bail\u00e9n","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0150","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1016\/j.bmc.2013.06.054","article-title":"Rapid modifications of N-substitution in iminosugars: development of new beta-glucocerebrosidase inhibitors and pharmacological chaperones for gaucher disease","volume":"21","author":"Cheng","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0155","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1039\/D0OB01522A","article-title":"Concise asymmetric synthesis of new enantiomeric C -alkyl pyrrolidines acting as pharmacological chaperones against gaucher disease","volume":"18","author":"Castellan","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0160","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3","article-title":"Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors","volume":"37","author":"Mammen","year":"1998","journal-title":"Angew. Chemie - Int. Ed."},{"key":"10.1016\/j.bioorg.2024.107295_b0165","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1039\/B815408B","article-title":"Multivalent iminosugars to modulate affinity and selectivity for glycosidases","volume":"7","author":"Diot","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/tcr.201900004","article-title":"Multivalent effect in glycosidase inhibition: the end of the beginning","volume":"20","author":"Compain","year":"2020","journal-title":"Chem. Rec."},{"key":"10.1016\/j.bioorg.2024.107295_b0175","doi-asserted-by":"crossref","first-page":"11616","DOI":"10.1002\/chem.201402537","article-title":"Multivalent inhibitors for Carbohydrate-processing enzymes: beyond the \u201clock-and-key\u201d concept","volume":"20","author":"Gouin","year":"2014","journal-title":"Chem. - A Eur. J."},{"key":"10.1016\/j.bioorg.2024.107295_b0180","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1039\/C5OB01405K","article-title":"Emerging trends in enzyme inhibition by multivalent nanoconstructs","volume":"13","author":"Kanfar","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0185","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.tetlet.2016.10.080","article-title":"Are enzymes sensitive to the multivalent effect?","volume":"57","author":"Matassini","year":"2016","journal-title":"Emerging Evidence with Glycosidases, Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2024.107295_b0190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","article-title":"Insights into the structural biology of gaucher disease","volume":"298","author":"Smith","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bioorg.2024.107295_b0195","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cbic.201200005","article-title":"Cyclodextrin-based Iminosugar click clusters: the first examples of multivalent Pharmacological chaperones for the treatment of lysosomal storage Disorders","volume":"13","author":"Decroocq","year":"2012","journal-title":"ChemBioChem."},{"key":"10.1016\/j.bioorg.2024.107295_b0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cbic.201300442","article-title":"A systematic investigation of Iminosugar click clusters as Pharmacological chaperones for the treatment of gaucher disease","volume":"15","author":"Joosten","year":"2014","journal-title":"ChemBioChem."},{"key":"10.1016\/j.bioorg.2024.107295_b0205","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200077","article-title":"3,4,5-Trihydroxypiperidine based multivalent glucocerebrosidase (GCase) enhancers","volume":"23","author":"Vanni","year":"2022","journal-title":"ChemBioChem."},{"key":"10.1016\/j.bioorg.2024.107295_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112173","article-title":"Synthesis of multimeric pyrrolidine iminosugar inhibitors of human \u03b2-glucocerebrosidase and \u03b1-galactosidase a: first example of a multivalent enzyme activity enhancer for fabry disease","volume":"192","author":"Mart\u00ednez-Bail\u00e9n","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0215","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202301210","article-title":"Phosphorus Dendrimers for metal-free ligation: Design of Multivalent Pharmacological Chaperones against gaucher disease","volume":"29","author":"Tran","year":"2023","journal-title":"Chem. \u2013 A Eur. J."},{"key":"10.1016\/j.bioorg.2024.107295_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103026","article-title":"Structural basis of the inhibition of GH1 \u03b2-glucosidases by multivalent pyrrolidine iminosugars","volume":"89","author":"Mart\u00ednez-Bail\u00e9n","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0225","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1021\/ol100774p","article-title":"Synthesis of a DOTA\u2212Biotin conjugate for radionuclide chelation via cu-free click chemistry","volume":"12","author":"Schultz","year":"2010","journal-title":"Org. Lett."},{"key":"10.1016\/j.bioorg.2024.107295_b0230","first-page":"1","article-title":"Strain-promoted 1,3-Dipolar cycloaddition of cycloalkynes and organic azides","volume":"374","author":"Dommerholt","year":"2016","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0235","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.3390\/molecules27175420","article-title":"Multivalent pyrrolidine Iminosugars: synthesis and biological relevance","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.bioorg.2024.107295_b0240","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1039\/C5QO00084J","article-title":"CuBr 2 -catalyzed enantioselective routes to highly functionalized and naturally occurring allenes","volume":"2","author":"Tang","year":"2015","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.bioorg.2024.107295_b0245","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1039\/b813414f","article-title":"Modular synthesis of multivalent glycoarchitectures and their unique selectin binding behavior","author":"Papp","year":"2008","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bioorg.2024.107295_b0250","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1016\/j.biomaterials.2014.01.014","article-title":"A multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and dengue virus","volume":"35","author":"Varga","year":"2014","journal-title":"Biomaterials."},{"key":"10.1016\/j.bioorg.2024.107295_b0255","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/acsmedchemlett.8b00602","article-title":"Stereoselective synthesis of C-2 alkylated Trihydroxypiperidines: novel Pharmacological chaperones for gaucher disease","volume":"10","author":"Clemente","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107295_b0260","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry."},{"key":"10.1016\/j.bioorg.2024.107295_b0265","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid \u03b2-glucosidase with pharmacological chaperone provides insight into gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107295_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms24109105","article-title":"Potential binding sites of Pharmacological chaperone NCGC00241607 on mutant \u03b2-glucocerebrosidase and its efficacy on patient-derived cell cultures in gaucher and Parkinson\u2019s disease","volume":"24","author":"Kopytova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107295_b0275","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202102359","article-title":"Design, synthesis and structural analysis of glucocerebrosidase imaging agents","author":"Rowland","year":"2021","journal-title":"Chem. \u2013 A Eur. J."},{"key":"10.1016\/j.bioorg.2024.107295_b0280","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1021\/jacs.7b13003","article-title":"\u03b2-Glucocerebrosidase modulators promote Dimerization of \u03b2-glucocerebrosidase and reveal an allosteric binding site","volume":"140","author":"Zheng","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2024.107295_b0285","first-page":"936","article-title":"Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing","volume":"47","author":"Carmichael","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107295_b0290","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera?A visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2024.107295_b0295","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2024.107295_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-7-339","article-title":"Tools for integrated sequence-structure analysis with UCSF Chimera","volume":"7","author":"Meng","year":"2006","journal-title":"BMC Bioinformatics."},{"key":"10.1016\/j.bioorg.2024.107295_b0305","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1107\/S0907444906038303","article-title":"Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in gaucher disease","volume":"62","author":"Brumshtein","year":"2006","journal-title":"Acta Crystallogr. d. Biol. Crystallogr."},{"key":"10.1016\/j.bioorg.2024.107295_b0310","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/jm051197e","article-title":"MolDock: a new technique for high-Accuracy Molecular docking","volume":"49","author":"Thomsen","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824002001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824002001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T11:25:19Z","timestamp":1712661919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824002001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":62,"alternative-id":["S0045206824002001"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107295","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multivalent pyrrolidines acting as pharmacological chaperones against Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107295"}}